Download PDF
Arzneimittelforschung 2008; 58(1): 18-23
DOI: 10.1055/s-0031-1296461
Antiallergic Drugs · Antiasthmatics · Antitussives · Bronchodilators · Bronchosecretogogues · Mucolytics
Editio Cantor Verlag Aulendorf (Germany)

Suppressive Activity of Pemirolast Potassium, an Antiallergic Drug, on Glomerulonephritis

Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis
Tomohito Gohda
1   Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
,
Chisei Ra
2   Division of Molecular Cell Immunology and Allergology, Nihon University Graduate School of Medical Sciences, Tokyo, Japan
,
Chieko Hamada
1   Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
,
Toshinao Tsuge
1   Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
,
Hiroshi Kawachi
3   Department of Cell Biology, Institute of Nephrology Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Niigata, Japan
,
Yasuhiko Tomino
1   Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)

    Permissions and Reprints

Abstract

Background:

It is still difficult to manage chronic glomerulonephritis with corticosteroids because of safety concerns, especially for patients with mild symptoms and infants. Therefore, an alternative approach is greatly required. Pemirolast potassium (CAS 100299-08-9) is an antiallergic drug with high safety.

Methods:

Two glomerulonephritis rat models were prepared to examine the pharmacological actions of pemirolast potassium: one reversible model prepared with the anti-Thy-1 antibody, and another irreversible model by unilateral nephrectomy and with the anti-Thy-1 antibody. Pemirolast potassium was administered to 10 Japanese chronic glomerulonephritis patients concurrently affected by allergic rhinitis in order to examine its efficacy for mild proteinuria.

Results:

Pemirolast potassium 1 and 10 mg/kg markedly inhibited proteinuria in the reversible model. In the irreversible model, pemirolast potassium 3 mg/kg showed a significant decrease in the incidence of glomerulosclerosis. In chronic glomerulonephritis patients, pemirolast potassium, 10 mg twice daily, for 6 months, significantly reduced the severity of proteinuria.

Conclusion:

Our research suggested the efficacy of pemirolast potassium in glomerulonephritis. A well-controlled study is considered necessary to validate pemirolast potassium as a therapeutic drug for glomerulonephritis.

Key words

Alegysal® - Antiallergic drugs - CAS 100299-08-9 - Glomerulonephritis, anti-Thy-1 antibody, experimental - Pemirolast potassium, efficacy in glomerulonephritis - Steroids
 

  • References

  • 1 Uzu T, Harada T, Ko M, Yamato M, Takahara K, Yamauchi A. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria. Clin Exp Nephrol. 2003; 7: 210-214
    CrossrefPubMedGoogle Scholar
  • 2 Nolin L, Courteau M. Management of IgA nephropathy. evidence-based recommendations. Kidney Int.. (Suppl. 999) 70: S56-62
    PubMedGoogle Scholar
  • 3 Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Ya-nase T et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003; 41: 972-983
    CrossrefPubMedGoogle Scholar
  • 4 Kawashima T, Iwamoto I, Nakagawa N, Tomioka H, Yoshida S. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Appl Immunol. 1994; 103: 405-409
    CrossrefPubMedGoogle Scholar
  • 5 Kawashima T, Matsui W. Inhibitory effect of TBX on leukocytes Emigration into pouch fluids in air-pouch allergic reaction. Jpn Pharmacol Ther. 1995; 23: 117-120
    PubMedGoogle Scholar
  • 6 Miyazawa N, Umemura K, Kondo K, Nakashima M. Effects of pemirolast and tranilast on intimai thickening after arterial injury in the rat. J Cardiovasc Pharmacol. 1997; 30: 157-162
    CrossrefPubMedGoogle Scholar
  • 7 Ohsawa H, Noike H, Kanai M, Yoshinuma M, Mineoka K, Hitsumoto T et al. Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 1998; 136: 1081-1087
    CrossrefPubMedGoogle Scholar
  • 8 Takishima T., Shirato K., Tamura G.. Med. Cons. New Remed. Post-marketing surveillance of pemirolast potassium (TBX) in adult bronchial asthma. Med Cons New Remed. 1994; 31: 2039-2052
    PubMedGoogle Scholar
  • 9 Nakamura T, Obata I, Kimura H, Ohno S, Yoshida Y, Kawachi H et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int. 1999; 55: 877-839
    CrossrefPubMedGoogle Scholar
  • 10 lefferson JA, Johnson RJ. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). I Nephrol. 1999; 12: 297-307
    PubMedGoogle Scholar
  • 11 Nagata M, Nagata T, Onimaru T, Tanaka K, Ohnishi M, Kakimoto D et al. 13-Week oral subacute toxicity studies followed by 5-week recovery test of TBX in beagles. Jpn Pharmacol Ther. 1989; 17: 1153-1181
    PubMedGoogle Scholar
  • 12 Nagata M, Nagata T, Onimaru T, Tanaka K, Ohnishi M, Kakimoto D et al. Chronic toxicity study of TBX in beagles administered orally for 52 weeks. Jpn Pharmacol Ther. 1989; 17: 1183-1204
    PubMedGoogle Scholar
  • 13 Watanabe M, Kanitani M, Kobayashi Y, Taki M, Minematsu S, Maemura S et al. Combined effect of glucocorticoid and TJ-114 (Tsumura Sairei-to). Nippon Yakurigaku Zasshi. 1993; 101: 39-51
    CrossrefPubMedGoogle Scholar
  • 14 Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford IE, Woodman P et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of tran-srepression from transactivation activity. J Immunol. 2001; 166: 1975-1982
    PubMedGoogle Scholar
  • 15 Lai KN, Lai FM, Ho CR, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol. 1986; 26: 174-180
    PubMedGoogle Scholar
  • 16 Welch TR, Fryer C, Shely E, Witte DP, Quinlan M. Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr. 1992; 121: 474-477
    CrossrefPubMedGoogle Scholar
  • 17 Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli D et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353: 883-887
    CrossrefPubMedGoogle Scholar
  • 18 Steel RGD. A multiple comparison rank sum test: Treatment versus control. Biometrics. 1959; 15: 560-572
    CrossrefPubMedGoogle Scholar